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Abstrak. Metabolic syndrome (MS) is a metabolic disorder caused by obesity and insulin 
resistance. In the state of obesity and insulin resistance occurs increased fat metabolism that 
causes production reactive oxygen species (ROS) and oxidative stress that makes dysregulation 
of adipose tissue that decreases antioxidant enzymes and immune system disorders. In diabetes 
mellitus there is pancreatic β cell damage caused by pro-inflammatory cytokines i.e 
interleukin-21 (IL-21). Black cumin seed oil (BCSO) contains antioxidants and 
immunomodulators but has not seen how it affects to IL-21. This study used cross over design 
to determine the effect of BCSO with dose of 1.5 mL/day and 3 mL/day dose of IL-21 in MS 
patients. The total subjects 66 of MS patients were divided into 2 groups. Group I was 
administered 1.5 mL/day and 3 mL/day of BCSO in dosage for 20 days and continued with 
washing out (BCSO discontinued) for 7 days. On the  day 28, group I administrated 3 mL/day 
of BCSO and group II were given 1.5 mL/day of BCSO  during 20 days. Statistical analysis 
showed that mean value  expression of IL-21 were given by BCSO at dose 1.5 mL/day was 
5.06±5.48 and BCSO at dose 3 mL/day 4.66±3.63 (p<0.05). The result showed that IL-21 
expression in patient at risk of MS who received BCSO dose 3 mL/day were lower than those 
received adose of 1.5 mL/day for 20 days.  
Keywords: black cumin seed oil, interleukin-21, metabolic syndrome risk 
1.  Introduction  
Metabolic syndrome (MS) is a set of abnormalities involving various physiological, biochemical, 
clinical and metabolic factors that can lead to the development of cardiovascular disease and diabetes 
mellitus and all-cause mortality risk [1]. Some of the risks causing MS include lifestyle (diet, smoking, 
physical activity), genetics and socioeconomics [2]. MS in Indonesia is one of the main public health 
problems such as diabetes mellitus, central obesity, dyslipidemia, and hypertension, which is a 
component of MS and has an effect on the prevalence of metabolic syndrome. MS case rate in 
Indonesia reached 23% i.e 26.6% in women and 18.3% in men of productive age, this data is based on 
the result of basic health research [3]. 
The pathophysiology of metabolic syndrome is not known for certain, but some literature say that 
the primary reason is a person's obesity state. Excess fat in the body causes increased fat metabolism 
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along with reactive oxygen species (ROS) production as well as increased oxidative stress 
characterized by a balance disorder of oxidation reduction reactions and decreased antioxidant 
enzymes in both adipose and tissue cells, this situation occurs in hypertension and atherosclerosis [4]. 
In addition, fat cell enlargement will secrete metabolic products such as pro-inflammatory 
cytokines, procoagulants, inflammatory peptides and angiotensinogen [5]. Insulin resistance affects 
type 2 of diabetes and hyperglycemia. A person with diabetes, oxidative stress will inhibit the taking 
of glucose in muscle cells and fat cells and decrease insulin secretion by pancreatic β cells (type 2 
diabetes). This is due to autoimmune disorders mediated by lymphocytes T and activated dendric cells 
involving inflammatory pathways Thelper1 (Th1), Thelper2 (Th2) and Thelper17 (Th17) and 
inhibition of T regulators. It is found that the Th17 pathway is involved in the inflammatory process 
and damage to pancreatic beta cells regulated by interleukin-21, interleukin-23 and interleukin-27. 
Interleukin-21 is a type 1 of cytokine [6, 7]. 
BSCO contains antioxidant and immunomodulatory substances which can be used as antidiabetes 
mellitus [8]. The main content of BSCO is essential oils such as timokuinon that have an effect on the 
immune system through inhibition of translocation of NF-kB into the nucleus so as to decrease pro-
inflammatory cytokines, chemokines, adhesion factors and coagulation factors[8]. In addition, it is 
known that BSCO can decrease the oxidative stress condition that triggers the synthesis of pro-
inflammatory cytokines through adhesion molecules. Interleukin-21 is a pro-inflammatory cytokine 
that plays a role in pancreatic B cell damage but it is not yet known how the effect of BSCO with a 
dose of 1.5 mL/day and 3 mL/day for 20 days in patients with metabolic syndrome risk. 
2. Materials and Methods
This study used cross over design with a total of 66 patients with metabolic syndrome who state 
willing to follow the study by agreeing inform consent. The inclusion criteria were obesity, blood 
pressure ≥140/90 mmHg, triglyseride level ≥150 mg/dL or using the drug of methabolic syndrom and 
18-70 years old. Exclusion criteria  werepregnant and lactating women, tuberculosis and be trought 
immun disease. But during the course of the study there were 4 patients who were excluded due to 
side effects such as nausea, vomiting, gastritis, increased blood pressure and decreased kidney 
function. This research was conducted at Jetis I Public Health Centers, Bantul Regency, Yogyakarta in 
August 2016 until March 2017. This clinical trial protocol has been reviewed and approved by health 
research ethics committee of Faculty of Medicine and Health Sciences, Universitas Muhammadiyah 
Yogyakarta with approval number 279/EP-FKIK-UMY/VIII/2016.  
Blood steering patients were taken from vena cubity by analysts in laboratory of the Jetis I Public 
Health Centers, Bantul Regency, Yogyakarta. Procedures undertaken in the implementation have been 
reviewed by research ethics committee of Universitas Muhammadiyah Yogyakarta. Blood that has 
been accommodated in a vacutainer containing anticoagulants is taken to the pharmacology laboratory 
of Universitas Gadjah Mada (UGM) and ready to be examined with flow cytometer. Here is the 
scheme of research implementation: 
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Figure 1. Schematic of research design 
3. Results and Discussion
3.1.The characteristics data of patients at risk of metabolic syndrome at Jetis I Public Health Centers, 
Bantul Regency in 2016 
From the previous studies, demographic data and characteristic data of metabolic syndrome as primary 
outcome and percentage of IL-21 expression as outcome secunder. From the data, statistical test using 
Chy-Square test and paired T-test sample with 95% confidence level. 
This research is conducted at Jetis 1 Public Health Centers, Bantul Regency, Yogyakarta in August 
2016 - March 2017. We involved doctors in getting patients who will be joined in the research and 
obtained a total of 66 patients at risk of metabolic syndrome who have met the inclusion and exclusion 
criteria. However, during the study there were 4 patients who drop out because they complain the side 
effects such as nausea, vomiting, gastritis, increased blood pressure and decreased kidney function. 
The total subjects who followed the study to the end were 62 patients at risk of metabolic syndrome. 
Table 1 shows the characteristics of patients at risk of metabolic syndrome. Based on gender, it is 
known that the metabolic syndrome was mostly suffered by women (78.80%) compared to men 
(21.20%). Metabolic syndrome was also more prevalent in the age group 51-60 years (42.40%), 
married status (98.50%), high school education (78.80%) and employment status (57.60). This result is 
in line with research conducted before [9] which reported that there was a significant relationship 
among gender, age, and work with the incidence of metabolic syndrome. Metabolic syndrome is more 
risky in women than in men. In women there is an excessive accumulation of fat in the adipose tissue 
that causes hypertriglyceride. Metabolic syndrome in women is also caused by diet, genetics and lack 
of physical activity than men [9, 10]. Women are more at risk of developing diabetes mellitus due to 
body mass index (BMI) that is more easily increased and the distribution of body fat easily 
accumulated due to hormonal processes in the body [11]. 
66 patients with metabolic syndrome 
On the 0th day blood sampling is performed to examine 
baseline data and characteristics of MS 
33 patients were given BCSO 1.5 mL/day for 
20 days 
33 patients were given BCSO 3 mL/day for 
20 days 
On the  day 21 patient blood was taken for 
examination of IL-21 expression 
On the  day 21 patient blood was taken for 
examination of IL-21 expression 
Washed out for 7 days  
(BCSO administration discontinued) 
Washed out for 7 days  
(BCSO administration discontinued) 
n
31 patients were given by 3 mL/day of 
BCSO for 20 days as group I 
31 patients were given by 1.5 mL/day of 
BCSO for 20 days as group II 
On the 49
th
 day blood samples were taken for 
examination of IL-21 expression 
On the 49
th
 day blood samples were taken for 
examination of IL-21 expression 
Data analysis 
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Table 1. The characteristics data of patients at risk of metabolic syndrome at 
Jetis I Public Health Centers in 2016 
Characteristics of patients n=66 Percentage 
(%) 
Gender 
Men 
Women 
14 
52 
21.20 
78.80 
Age 
<41 years old 
41-50 years old 
51-60 years old 
>60 years old 
1 
20 
28 
17 
1.50 
30.30 
42.40 
25.80 
Marital status 
Married 
Single 
65 
1 
98.50 
1.50 
Education  
No school 
Elementary-High School 
College-Master 
6 
52 
8 
9.10 
78.80 
12.10 
Working  
Work  
Not working 
38 
28 
57.60 
42.40 
The incidence of metabolic syndrome is more experienced by age group > 40 years than age < 40 
years [9]. Metabolic syndrome occurs as one gets older. This is due to a decrease in organ function and 
metabolic disorders that exist in the body. Diabetes mellitus occurs due to decreased insulin secretion 
because of the pancreatic β cells damage, insulin resistance, impaired metabolism of carbohydrates, 
proteins and fats and reduced elasticity of blood vessels may be at risk of hypertension and 
atherosclerosis leading to the incidence of metabolic syndrome [9, 12, 13]. Metabolic syndrome has a 
significant relationship with one's marital status [14, 15]. A married person will be faced with a social 
environment that allows problems and causes unhappiness. Each problem will create psychosocial 
stress potential that may be at risk of metabolic syndrome [15]. Education and work are two 
characteristics of metabolic syndrome which has interconnected each other. Education can determine 
the type of work of a person with different income to meet their daily needs. Lifestyle change can 
increase the prevalence of diseases such as diabetes, obesity and heart disease which is a factor risk of 
metabolic syndrome [16]. Job status relates to daily physical activity. In this study, patients with 
metabolic syndrome are more likely than workers, such as civil servants, entrepreneurs, farmers, 
fishermen and laborers with mild to severe activity. Physical activity can help lower cholesterol, 
triglycerides, increase HDL and insulin sensitivity and lower blood pressure which is a risk factor for 
the incidence of metabolic syndrome and cardiovascular disease complications [17]. 
Table 2 shows the characteristics data of patients with metabolic syndrome. Metabolic syndrome is 
more prevalent in patients at risk of metabolic syndrome with prolonged <5 years (59.10%) compared 
with 5 years of age (40.90%). Patients at risk for metabolic syndrome who participate in this study 
mostly suffered from diabetes mellitus with complications. Diabetes mellitus is a metabolic disease 
with characteristics of hyperglycemia due to abnormalities of insulin secretion and become a risk 
factor for organ damage and dysfunction especially in the eyes, kidneys, nerves, heart and blood 
vessels. 
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Table 2. The characteristics data of patients at risk of metabolic syndrome at Jetis I Bantul Public 
Health Centers in 2016 
Characteristics of patients n=66 Percentage(%) 
Characteristics of metabolic syndrome  
DM 
Hypertension  
Hypertriglyceride  
DM+ Hypertension 
DM+ Hypercholesterolemia 
DM+ Obesity 
DM+ Hypertriglyceride 
DM+ Dyslipidemia 
DM+ Hypertension + Hypertriglyceride 
DM+ Hypertension + Hypercholesterolemia 
DM+ Hypertension + Obesity 
DM+ Hypertension + Dyslipidemia 
DM+ Hypertension + Hypertriglyceride + Obesity 
10 
1 
1 
16 
2 
1 
6 
3 
12 
5 
2 
5 
2 
15.20 
1.50 
1.50 
24.20 
3.00 
1.50 
9.10 
4.50 
18.20 
7.60 
3.00 
7.60 
3.00 
Routine Medication 
DM Drug 
Hypertension Drug 
Dyslipidemia Drug 
DM Drug+ Hypertension Drug 
DM Drug +Dyslipidemia Drug 
DM Drug + Hypertension Drug + Dyslipidemia Drug 
25 
1 
1 
33 
3 
3 
37.90 
1.50 
1.50 
50.00 
4.50 
4.50 
3.2. Clinical examination result of patients at risk of metabolic syndrome before and after using BCSO 
Dose 1.5 mL/day and 3 mL/day 
Patients at risk of metabolic syndrome before treatment are examined clinical conditions such as 
systolic and diastolic blood pressure, pulse rate, body mass index (BMI), using a tool that has been 
calibrated by the calibration laboratory of Universitas Ahmad Dahlan Yogyakarta. Examination 
of blood glucose level (BG), triglyceride level (TG) and SGOT and SGPT activity using 
5010 spectrophotometer at the laboratory of Jetis I Public Health Centers, Bantul Regency, 
Yogyakarta. The data were analyzed using repeated measure ANOVA test and continued with 
Bonferroni test as shown in Table 3. 
Table 3. The results of measurement of clinical condition of patients at risk of metabolic syndrome 
before and after using BCSO dose 1.5 mL/day and 3 mL/day at Jetis I Public Health Centers, Bantul 
Regency, Yogyakarta in 2016 
Clinical Conditions of Patients 
Average ± SD, n=62 p Values 
Pretreatment Dose 1.5 mL/day Dose 3 mL/day 
SBP(mmHg) 143.06±17.98
a 
137.73±17.66 136.92±17.66 0.00 
DBP(mmHg) 80.78±9.25 79.27±13.96 79.95±10.98 0.58 
Pulse (x/min) 88.66±13.82
a 
90.69±12.91 92.44±12.15 0.04 
BMI (kg/m
2
) 24.16±4.13
a 
24.79±4.27 24.35±5.10 0.00 
BG (mg/dL) 246.69±109.30
ab 
184.18±89.46 197.77±87.14 0.00 
TG (mg/dL) 193.84±114.61
a 
173.42±108.51 158.58±97.87 0.00 
SGOT (U/L) 23.00±10.41 21.82±6.47 22.60±9.95 0.63 
SGPT (U/L) 22.29±10.81 21.16±7.86 21.03±12.08 0.82 
Description: a= there is a significant difference between the measurement before treatment and the dose 
measurement 3 mL/day; B= there is a significant difference between the measurement before 
treatment and the dose measurement of 1.5 mL/day. 
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The results of statistical analysis show that there are significant differences between measurement 
of systolic blood pressure (SBP), pulse, BMI, BG and TG before and after BCSO administration in 
patients at risk of metabolic syndrome (p<0.05). The results of statistical analysis show that there is no 
significant difference between diastolic blood pressure (DBP) measurement, SGOT and SGPT 
activities before and after BCSO administration in patients at risk of metabolic syndrome (p>0.05). 
These results indicate that giving BCSO dose of 1.5 mL/day and 3 mL/day for 20 days can decrease 
the mean blood pressure value in patients at risk of metabolic syndrome with targeted therapy <140/90 
mmHg. This is in line with research conducted which states that the provision of black cumin seed 
powder can reduce blood pressure during 20 days of administration in patients with metabolic 
syndrome [18]. Another study mentioned that giving black seeds of cumin seeds for 8 weeks can 
reduce the blood pressure of cytolic and diastolic without side effects [19]. This study shows that 
black seeds of cumin seeds for 20 days are able to increase pulse rate and BMI in patients at risk of 
metabolic syndrome but still within normal limits. According to the American Heart Association 
(AHA) the normal range of pulse rate is 60-100 x/min and according to the World Health Organization 
(WHO) the normal value of IMT in patients at risk of metabolic syndrome is <30 kg/ m2. The results 
of this study stated that the administration of BCSO dose 1.5 mL/day and 3 mL/day for 20 days can 
reduce blood glucose levels in time and triglycerides in patients at risk of metabolic syndrome. BCSO 
contains active compounds such as thymoquinone, nigelon and thymol which play a role in lowering 
blood glucose. Black cumin in adipose cells can stimulate the secretion of insulin produced by 
pancreatic cells and is shown to have no effect on tissue sensitivity to glucose [20]. Criteria for 
metabolic syndrome according to International Education DiabetesFederation (IDF) in hypertension, 
triglycerides >150 mg/dL, HDL for women < 50 mg/dL and men < 40 mg/dL or  in treatment of 
tubercidemia, diagnosed type 2 DM with GDP > 100 mg/dL [21]. 
Statistical analysis shows that SGOT and SGPT activities in patients at risk of metabolic syndrome 
decrease after using  BCSO dose 1.5 mL/day and 3 mL/day for 20 days but not statistically significant 
(p>0,05). This is because the patients who participate in this study had a mean value of SGOT and 
SGPT activity in normal limits. The incidence of metabolic syndrome is associated with fatty liver 
disease or NAFLD. In patients with insulin resistance will experience steatosis due to increased free 
fatty acids to the liver increased. Oxidative stress and cytokines can cause disruption to the function of 
cells and liver organ [22]. SGOT and SGPT can be an indicator of liver damage with SGOT values 
<35 U/L and SGPT <41 U/L.  
3.3. Measurements of IL-21 expression in patients at risk of metabolic syndrome given BCSO dosage 
1.5 mL/day and 3 mL/day 
Measurements of IL-21 expression using a flow cytometer tool in the pharmacology laboratory of the 
Faculty of Medicine, Universitas Gajah Mada (UGM), Yogyakarta. Data on IL-21 expression 
measurements in patients at risk of metabolic syndrome given BCSO dose 1.5 mL/day and 3 mL/day 
for 20 days statistically analyzed using paired T-test as shown in Table 4. 
Table 4. The results of IL-21 expression measurements in patients at risk of metabolic syndrome 
given BCSO dose 1.5 mL/day and 3 mL/day for 20 days 
Clinical condition patient 
Mean value ± SD p 
Value Dose 1.5 mL/day 
(n=62) 
Dose 3 mL/day 
(n=62) 
IL-21 5.06±5.48 4.66±3.63 0.69 
The results of statistical analysis shows that the mean value of IL-21 expression in patients at risk 
of metabolic syndrome who received BCSO dose 3 mL/day was lower than those who received BCSO 
dose 1.5 mL/day but not statistically significant (p>0.05). Several factors that may influence the 
research results are the possibility of influence from previous treatment before cross over design on 
BCSO dose 1.5 mL/day and 3 mL/day for 20 days. Physiological conditions of the body and lifestyle 
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such as lack of exercise, smoking and taking drugs for long periods in patients at risk of metabolic 
syndrome can also affect the results of the study. 
Metabolic syndrome occurs because of insulin resistance. This is due to the disruption of pancreatic 
β cell function and insulin hypersecretion resulting in insulin resistance, in addition to severe damage 
to pancreatic β cells that leads to decreased insulin production and hyperglycemia. The deficiency of 
IL-21 expression in diabetic nonobese mice (NOD) may lead to resistance to insulitis, insulin 
autoantibody production and the onset of type I diabetes [7]. Excess of IL-21 expression in pancreatic 
β cells makes of inducing chemokines, inflammatory cytokines such as IL-17A, IL-17F, IFN-gamma, 
monocyte chemoattractant protein (MCP)-1 and MCP-2. IL-21 is a type I cytokine produced by T-
cells and NK cells and is detected in CD4
+
 and T-helper undergoing differentiation [23]. 
Giving Nigela sativa L. can cause demodulator in pro-inflammatory cytokines produced by T-
helper-1 and cytokines. The active substance contained in the BSCO can evoke the immune system 
with the ability to raise T-helper cell, Tsupressor cells, and NK cells are a product of lymphocytes [24, 
25]. T-cells play an important role in inducing inflammation induces makrofaf and secrete 
inflammatory and pro-inflammatory cytokines in adipose tissue leads to insulin resistance and lead to 
diabetes mellitus. Inflammatory cytokines would improve insulin resistance through the role of 
inflammatory signals such as janus kinase (JK) and activation of transcription factors nuclearfactor 
kappaB (NF-kB). Signaling pathways such as JK and NF-kB may reduce the action of insulin in 
adipocyte tissue [26, 27]. 
Black cumin seed can be utilized as an antioxidant and immunomodulator. Hexane extracts of 
black cumin seeds (Nigella sativa L.) can improve macrophage phagocytic activity in DMBA-induced 
female rats in vitro [8]. Part of the most widely used black cumin seed plant is its oil. Black cumin 
seed oil contains essential oil content of non polar thymoquinone that is 27.8% [28]. The working 
mechanism of thymoquinone is by inhibiting non-enzymatic lipid peroxidation in liposomes and has 
the potential to neutralize free radicals and inhibit the pro-inflammatory cytokines such as interleukin-
1β, interleukin-8 and chemokines such as machrophage chemotactic protein (MCP)-1 with the 
mechanism of action via inhibition of TNF- α which induces activation of transcription factors 
nuclearfactor kappaB (NF-kB) signaling pathway is involved in IL-21 and inhibiting the translocation 
of NF-kB into the nucleus [29]. BCSO delivery in the metabolic syndrome will inhibit IL-21 
activation by decreasing the deference of T-helper which also produces IL-21 (IL-21R) receptors as 
well as inhibition of the STAT 3 signaling pathway. 
4. Conclusion
IL-21 expressions  in patients at risk of metabolic syndrome who received BCSO dose 3 mL/day were 
lower than those received a dose of 1.5 mL/day for 20 days. 
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